AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03404817
Drug: Original formulation EMB-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose (720 mg metyrapone/24 mg oxazepam)
Trial: NCT03404817
Drug: New formulation EMB-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose (720 mg metyrapone/24 mg oxazepam)
Trial: NCT03523819
Drug: CS1002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose levels will be escalated following a modified 3+3 dose escalation scheme
Trial: NCT02954536
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03381144
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive GDC-0334-matching placebo.
Trial: NCT04106297
Drug: GLPG3970 oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG3970 for oral administration
Trial: NCT04106297
Drug: Placebo oral solution
RxNorm normalized name: Placebo Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for oral administration
Trial: NCT04106297
Drug: GLPG3970 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG3970 for oral administration
Trial: NCT03025282
Drug: CD10367 3% Solution - Non-desquamated zone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application for 3 weeks
Trial: NCT03025282
Drug: CD10367 1% Solution - Non-desquamated zone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application for 3 weeks
Trial: NCT03025282
Drug: CD10367 solution placebo - Non-desquamated zone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application for 3 weeks
Trial: NCT03025282
Drug: CD10367 3% Solution - Desquamated zone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application for 3 weeks
Trial: NCT03025282
Drug: CD10367 solution placebo - Desquamated zone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application for 3 weeks
Trial: NCT02194192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 10 ml
Trial: NCT01869907
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg once daily by mouth during 14 days
Trial: NCT01869907
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily by mouth during 14 days
Trial: NCT00193336
Drug: ZD1839
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03237481
Drug: HTX-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX 011 (bupivacaine/meloxicam), 300 mg/9 mg by instillation
Trial: NCT03237481
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo by instillation
Trial: NCT01584232
Drug: LY2189265
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04052594
Drug: LY3475766 - IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT04052594
Drug: Placebo - IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT01584232
Drug: Sulfonylureas (SU)
RxNorm normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00820014
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control (vehicle) eye drops applied 4-times a day for 4 days before ocular surgery
Trial: NCT00788684
Drug: ABT-263
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-263: oral solution or tablets, once daily dosing until disease progression
Trial: NCT03541850
Drug: Antiandrogen Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive luteinizing hormone-releasing hormone agonist or gonadotropin-releasing hormone antagonist, and oral anti-androgen
Trial: NCT00715039
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo p.o. t.i.d. for 28 days; placebo matching lorazepam and paroxetine
Trial: NCT02854072
Drug: GV1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At week 1, GV1001 will be administered intradermally on day 1, day 3 and day 5. This will be followed by a once weekly schedule for weeks 2, 3, 4 and 6. After that, GV1001 will be administered once monthly until withdrawal from trial treatment due to patient choice, intolerable toxicity or disease progression. GM-CSF will be used as an adjuvant, given 10-15 minutes prior to each administration of GV1001.
Trial: NCT02854072
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 830 mg/m\^2 will be orally given in the morning and evening (total dose of 1660 mg/m\^2) for 21 days followed by 7 days' rest.
Trial: NCT03442244
Drug: LEO 90100 foam
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each subject has each of the 2 treatments applied at the same time on 2 different sites on the back
Trial: NCT02570984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator arm, injection similar to active
Trial: NCT00335699
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03254589
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See arm descriptions
Trial: NCT03028766
Drug: AZD1775
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1775 is a potent, selective small molecule inhibitor of WEE1
Trial: NCT00115570
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection twice daily
Trial: NCT02182622
Drug: LDE225
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00271635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 4 capsules b.i.d. during 1 year
Trial: NCT00271635
Drug: ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 1000 mg (4 capsules of 250 mg) b.i.d. during 1 year
Trial: NCT02830724
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For Phase I, Days -7 and -6:~Dose Level 1: 15 mg/kg/day x 2 days IV Dose Level 2: 15 mg/kg/day x 2 days IV Dose Level 3: 15 mg/kg/day x 2 days IV Dose Level 4: 15 mg/kg/day x 2 days IV Dose Level 5: 30 mg/kg/day x 2 days IV Dose Level 6: 60 mg/kg/day x 2 days IV~For Phase II, Days -7 and -6:~60 mg/kg/day x 2 days IV
Trial: NCT04356222
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal chemotherapy specified dose on specified days
Trial: NCT01216176
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02918370
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredient matching the active comparators in appearance.
Trial: NCT01187017
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg
Trial: NCT00758732
Drug: Liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal doxorubicin at the dose of 20 mg/m2 over a 90 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
Trial: NCT02931188
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
Trial: NCT02931188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
Trial: NCT00683436
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01596296
Drug: Dinoprostone 10mg
RxNorm normalized name: DINOPROSTONE 10MG INSERT,VAG
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dinoprostone vaginal insertion
Trial: NCT01225874
Drug: SC-PEG E. coli L-asparaginase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IM
Trial: NCT00677469
Drug: Placebo powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gram BID
Trial: NCT01225874
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT
Trial: NCT03668340
Drug: AZD1775
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1775 blocks the activity of Wee1, a protein that helps to regulate how cells divide and grow. Certain cancer cells may be more vulnerable to having this process blocked
Trial: NCT04492033
Drug: CTX-009 (ABL001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTX-009 (ABL001) will be administered biweekly.
Trial: NCT04781335
Drug: Standard of Care post operative eye drops (steroid, antibiotic, NSAID)
RxNorm normalized name: Sx1 Medicated Post-Operative System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a contra-lateral randomized study, meaning that in clinic after a patient is identified as a candidate we will flip a coin for selection of the eye that is going to receive the Dexycu™ implant (the implant will be placed intracapsularly at the optic haptic junction of the IOL). The patients will receive the SAME topical regimen (Eye with Dexycu™: no steroid, Eye without Dexycu™: steroid will be used). The Dexycu™, topical NSAID, and antibiotic regimen will be provided to all patients in the study, at no cost, in order to avoid difficulties with compliance, insurance, and follow up.
Trial: NCT02098343
Drug: APR-246
RxNorm normalized name: PrameGel Reformulated Apr 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion.
Trial: NCT02098343
Drug: Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion.
Trial: NCT04389775
Drug: Cohort A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in each cohort (A1 to A6) will be randomised to receive a SC dose of XW003 on Day 1 after overnight fasting by body weight range:~1. Proposed XW003 Dose Levels (50 kg-75 kg): 0.03mg, 0.1mg, 0.2mg, 0.4mg, 0.8mg and 0.6mg respectively for Cohorts A1 to A6.~2. Proposed XW003 Dose Levels (76 kg-90 kg): 0.03mg, 0.1mg, 0.25mg, 0.5mg, 1.0 mg and 0.6mg.~These doses are subject to change following SRC review of each cohort - XW003 dose level will not exceed 2.0 mg.
Trial: NCT00245635
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets varying between 10mg and 80mg on a fixed/flexible dosing schedule based on the subjects' weight and side effects score.
Trial: NCT04389775
Drug: Placebo A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in each cohort (A1 to A6) will be randomised to receive a SC dose of volume-matching placebo on Day 1 after overnight fasting by body weight range:~1. Proposed Placebo Dose Levels (50 kg-75 kg): 0.03mg, 0.1mg, 0.2mg, 0.4mg, 0.8mg, and 0.6mg respectively for Cohorts A1 to A6.~2. Proposed Placebo Dose Levels (76 kg-90 kg): 0.03mg, 0.1mg, 0.25mg, 0.5mg, 1.0 mg and 0.6mg.~These doses are subject to change following SRC review of each cohort - dose level will not exceed 2.0 mg.
Trial: NCT04389775
Drug: Cohort B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in cohorts B1 to B3 (n=10 per cohort) will receive multiple SC doses of XW003 (n=8) once weekly for 6 weeks following an overnight fast of at least 10 hours.~1. Subject to change following SRC review of each cohort.~2. Following 4 weeks of once weekly dosing, the SRC will review the safety data (and PK data for Cohort B1 only) to determine the treatment for the following cohort and whether dosing can commence in parallel.~3. At least 3 days prior to Cohort B3 Week 3 (i.e., 3 days prior to the third dose in Cohort B3), the SRC will review the safety and PK data for Cohorts B1 and B2 to determine whether Cohort 3 dosing for Weeks 3 to 6 may commence.
Trial: NCT04389775
Drug: Placebo B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in cohorts B1 to B3 (n=10 per cohort) will receive multiple SC doses of matching placebo (n=2) once weekly for 6 weeks following an overnight fast of at least 10 hours.~1. Subject to change following SRC review of each cohort.~2. Following 4 weeks of once weekly dosing, the SRC will review the safety data (and PK data for Cohort B1 only) to determine the treatment for the following cohort and whether dosing can commence in parallel.~3. At least 3 days prior to Cohort B3 Week 3 (i.e., 3 days prior to the third dose in Cohort B3), the SRC will review the safety and PK data for Cohorts B1 and B2 to determine whether Cohort 3 dosing for Weeks 3 to 6 may commence.
Trial: NCT00245635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be given 1x/day for the duration of the study at a fixed/flexible dosing schedule similar to that for the drug fluoxetine based off of subjects' weight and side effects score.
Trial: NCT01590810
Drug: MK-8150 10 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 10-mg dose of MK-8150
Trial: NCT01590810
Drug: MK-8150 40 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 40-mg dose of MK-8150 without food (fasted) and with food (fed)
Trial: NCT01590810
Drug: MK-8150 90 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 90-mg dose of MK-8150
Trial: NCT01590810
Drug: MK-8150 5.0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 5.0-mg dose of MK-8150
Trial: NCT01590810
Drug: MK-8150 20 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 20-mg dose of MK-8150
Trial: NCT01590810
Drug: MK-8150 60 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 60-mg dose of MK-8150
Trial: NCT01590810
Drug: MK-8150 120 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 120-mg dose of MK-8150
Trial: NCT01590810
Drug: MK-8150 320 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 320-mg dose of MK-8150
Trial: NCT01590810
Drug: MK-8150 600 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 600-mg dose of MK-8150
Trial: NCT01590810
Drug: MK-8150 900 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 900-mg dose of MK-8150
Trial: NCT01590810
Drug: MK-8150 1200 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 1200-mg dose of MK-8150
Trial: NCT01590810
Drug: MK-8150 50 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 50-mg dose of MK-8150
Trial: NCT01590810
Drug: MK-8150 100 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 100-mg dose of MK-8150
Trial: NCT01590810
Drug: MK-8150 200 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 200-mg dose of MK-8150
Trial: NCT01590810
Drug: MK-8150 400 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 400-mg dose of MK-8150
Trial: NCT01590810
Drug: MK-8150 500 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 500-mg dose of MK-8150
Trial: NCT02669810
Drug: PROTHERACYTES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProtheraCytes endocardiac injections performed with the HELIX and Morph catheters
Trial: NCT02669810
Drug: Standard Treatment for CHF post AMI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01721135
Drug: GSK2190915 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film coated oral tablet
Trial: NCT01721135
Drug: GSK2190915 200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film coated oral tablet
Trial: NCT01721135
Drug: GSK2190915 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film coated oral tablet
Trial: NCT01293903
Drug: Qiliqiangxin capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qiliqiangxin capsule is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period.
Trial: NCT01293903
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, similar in color and taste to Qiliqiangxin capsule, is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period.
Trial: NCT02749396
Drug: Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Trial: NCT02749396
Drug: Extavia (interferon beta-1b), Novartis Pharma AG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Trial: NCT02749396
Drug: Rebif (interferon beta-1a), Merck Serono Europe Ltd
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Trial: NCT02749396
Drug: Plegridy (peginterferon beta-1a), Biogen Idec Ltd
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Trial: NCT02749396
Drug: Avonex (interferon beta-1a), Biogen Idec Ltd
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Trial: NCT02739230
Drug: On-Q pain intra-articular catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01277016
Drug: BMDex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMDex:~cycles 1 and 2 = MDex with bortezomib (B) at 1.3 mg/m2 i.v. on days 1, 4, 8 and 11 of a 28 day cycle, cycles 3 - 8 = MDex with bortezomib at 1.3 mg/m2 i.v. on days 1, 8, 15 and 22 of a 35 day cycle.
Trial: NCT00174876
Drug: Drug Abilify
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00440232
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert tab identical in appearance to Frovatriptan
Trial: NCT00481832
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 gm /m² IV over 2 hours on day 8
Trial: NCT00543842
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Starting Dose 650 mg/m\^2 By Mouth Twice Daily Monday-Friday x 6 Weeks
Trial: NCT06013735
Drug: guava leaves aqueous extract
RxNorm normalized name: guava extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guava leaves aqueous extract mouth rinse (0.5%)
Trial: NCT01654354
Drug: NEOVIST 370 INJ.(Iopromide 768.86mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01654354
Drug: Ultravist 370 INJ.(Iopromide 768.86mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04139330
Drug: NPC-06
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infuse NPC-06 intravenously
Trial: NCT05414461
Drug: Combinations
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitor-based combinaiton treatment
Trial: NCT00215904
Drug: D-serine (~2g/day)
RxNorm normalized name: D-Serine
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 6 weeks treatment arms. One arm: adjuvant treatment with D-serine (\~2g/day). Second arm : adjuvant treatment with placebo (\~2g/day).
Trial: NCT02884440
Drug: TAP block placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02884440
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml CISATRACURIUM 2mg/ml if necessary DEXAMETHASONE 8 mg KETAMINE 0,15mg/kg Maintenance PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml
Trial: NCT04039087
Drug: Placebo Oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule taken by mouth thrice daily
Trial: NCT02647099
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02647099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03377387
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be taken orally in AM and PM (at the assigned dose per cohort) 7 days on and 7 days off. Phase II MD 1000mg BID of capecitabine.
Trial: NCT02161614
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00743184
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo is also provided and reconstituted using diluent containing 0.1% saline solution.
Trial: NCT04188548
Drug: LY3484356
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01643070
Drug: Capecitabine, Oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy - Induction XELOX (Capecitabine 1250 mg/m2 PO twice daily on D1-14 and oxaliplatin 130 mg/m2 on D1, every 3 weeks for 2 cycles) Preoperative chemoradiotherapy - XELOX RT (Capecitabine 825 mg/m2 PO twice daily during radiotherapy and oxaliplatin 50 mg/m2/day on weekly.)